AT-3 Mouse Breast Tumor Cell Line
Summary:
NCI is seeking licensees for the AT-3 mouse breast tumor cell line.
Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a)
Summary:
NICHD is seeking licensees for development of an adeno-associated viral (AAV) vectors for the treatment of glycogen storage disease type Ia (GSD-Ia).
Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens
Description of Technology:
Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive type of non-Hodgkin lymphoma that mostly occurs in people between the ages of 30-40. It accounts for 5-7% of all aggressive lymphomas. The diagnosis of PMBCL is challenging as the histological features of PMBCL overlap with diffuse large B-cell lymphoma (DLBCL), another most common type of non-Hodgkin lymphoma. Available evidence suggests that PMBCL responds much more favorably to the DA-EPOCH-R chemotherapy regimen than to the standard R-CHOP regimen used to treat DLBCL.
A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma
Summary:
NCI seeks proposals from parties interested in co-development and licensing opportunities to employ biomarker viral exposure signature in diagnostic assays of early onset HCC.
A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer
Summary:
The NCI Laboratory of Cellular and Molecular Biology seeks statements of capability or interest from parties interested in licensing this novel inhibitor of the Hippo signaling pathway.
Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics
Description of Technology:
Hydrogels represent an attractive controlled drug-delivery system that have been used in various clinical applications, such as: tissue engineering for wound healing, surgical procedures, pain management, cardiology, and oncology. High-water content of hydrogels confers tissue-like physical properties and the crosslinked fibrillar network enables encapsulation of labile small molecule drugs, peptides, proteins, nucleic acids, proteins, nanoparticles, or cells.
Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides
Summary:
The NCI is looking for innovative companies interested in co-developing and/or licensing a novel nucleic-based therapy based on the conditional activation strategy.
Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276
Summary:
The National Cancer Institute (NCI) seeks research collaborations and/or licensees for the development of a CD276 antibody drug conjugate (ADC) for the treatment of solid tumors.
Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy
Description of Technology:
Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL), T cell receptor (TCR) and Chimeric Antigen Receptor (CAR) engineered T cells, or hematopoietic stem cell transplantation, is a promising new approach to cancer treatment. ACT harnesses an individual's adaptive immune system to fight against cancer, with fewer side-effects and more specific anti-tumor activity. Despite their promise of ACT as curative, these therapies are often limited by the persistence and robustness of the responses of the T cells to the cancer cells.
Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus
Description of Technology:
Gammaretroviral vectors were the first viral gene-therapy vectors to enter clinical trials and remain in use. One potential hazard associated with the use of such vectors is the presence of replication-competent retroviruses (RCR) in the vector preparations – either as a result of: 1) recombination events between the plasmids used for vector production, 2) interactions between the plasmids and endogenous retroviral sequences in the packaging cell lines, or 3) as a result of contamination in the laboratory.